# SpotitEarly

> SpotitEarly is a healthtech company building an accessible, non-invasive early cancer detection service that combines trained scent-detection beagles with an AI platform to analyze volatile organic compounds (VOCs) in a person's breath. Users collect a breath sample at home and mail it to the company's lab, where beagles screen for cancer-linked odors and SpotitEarly's proprietary LUCID bio-AI platform digitizes and interprets the dogs' behavioral signals. A double-blind clinical study of 1,400 people, published in Nature's Scientific Reports, reported 94% sensitivity and specificity across the four most common cancers - breast, colorectal, lung, and prostate. Founded in Israel and now launching in the U.S., the company aims to make routine multi-cancer pre-screening affordable, at roughly $250 for a single test.

- **Founded:** 2020
- **Headquarters:** Englewood, New Jersey, United States
- **Founders:** Shlomi Madar (CEO & Board Member (PhD, Weizmann Institute of Science)), Ariel Ben-Dayan (Co-founder (former K9 unit commander)), Roi Ophir (Co-founder, Active Chairman), Ohad Sharon (Co-founder, CSO Strategy), Udi Bobrovsky (Co-founder, COO)
- **Team size:** ~34 employees, plus 18 trained beagles
- **Products:** At-home multi-cancer breath test, LUCID bio-AI hybrid platform, BRCA germline testing
- **Notable:** Double-blind clinical study of 1,400 participants reporting 94% sensitivity and specificity across breast, colorectal, lung, and prostate cancer, Peer-reviewed results published in Nature's Scientific Reports (November 2024), Raised $20.3M to launch in the U.S. market ($34.3M total funding)

## Products & services

- **At-home multi-cancer breath test** — A mail-in breath sample kit collected at home. In the lab, trained beagles screen the sample for cancer-linked volatile organic compounds while the LUCID AI platform interprets their behavior. Screens for breast, colorectal, lung, and prostate cancer.
- **LUCID bio-AI hybrid platform** — Proprietary platform combining a multimodal sensor array with a deep-learning architecture that continuously monitors trained canines' behavioral and physiological signals (sniff duration, hesitation, posture) to generate scalable diagnostic outputs. LUCID 2.0 supports large-scale diagnostics.
- **BRCA germline testing** — Genetic testing offering to complement breath-based screening for hereditary cancer risk.

## Achievements

- Double-blind clinical study of 1,400 participants reporting 94% sensitivity and specificity across breast, colorectal, lung, and prostate cancer
- Peer-reviewed results published in Nature's Scientific Reports (November 2024)
- Raised $20.3M to launch in the U.S. market ($34.3M total funding)
- Selected as a TechCrunch Disrupt Startup Battlefield company (2025)
- Strategic research partnerships with Hackensack Meridian Health and Fox Chase Cancer Center

## Latest updates

- **2026-07** — Announced a partnership with HITLAB to accelerate its U.S. launch.
- **2025-10** — Featured as a Startup Battlefield company at TechCrunch Disrupt, demonstrating its dog-and-AI cancer detection technology.
- **2025-07** — Profiled by Forbes detailing its AI-and-dogs breath test and pricing (~$250 single test, ~$500 four-cancer panel).
- **2025-05** — Entered the U.S. market with $20.3M in funding and opened a Series A round under Regulation D.

## Links

- Website: https://spotitearly.com
- LinkedIn: https://www.linkedin.com/company/spotitearly
- Instagram: https://www.instagram.com/spotitearly/

---

Profile page: https://yespress.io/spotitearly
Published by YesPress — https://yespress.io
Last updated: 2026-07-18